All In Biotech

Drug Trial Radar · NCT07294235

A Study of BGM1812 Injection in Healthy and Non-diabetic Overweight or Obese Chinese Participants

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Tolerability, Safety and Pharmacokinetics of BGM1812 in Healthy and Non-diabetic Overweight or Obese Chinese Participants

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

60

Actual

Start

Dec 5, 2025

Primary completion

Jun 5, 2026

Study completion Jun 5, 2026

Sponsor

Sponsor type
Industry
First posted
Dec 19, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the tolerability , safety and pharmacodynamics of BGM1812 administered subcutaneously in healthy and non-diabetic overweight or obese Chinese participants, and to investigate the pharmacokinetic profile of BGM1812 in the bloodstream.

Conditions

  • Overweight or Obesity

Interventions

  • BGM1812Drug

    AdministeredSC

  • PlaceboDrug

    Administered SC

  • BGM1812Drug

    Administered SC

  • PlaceboDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the InvestigatorTime frame: Baseline to Study Completion (Up to 6-9weeks)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Yunnan University of Chinese Medicine

    Kunming, Yunnan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.